Rupnow MF - Search Results

1

Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States.

Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. Rupnow MF, et al. J Infect Dis. 2009 Oct 15;200(8):1311-7. doi: 10.1086/605845. J Infect Dis. 2009. PMID: 19751153

2

Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology.

Rupnow MF, Owens DK, Shachter R, Parsonnet J. Rupnow MF, et al. Helicobacter. 1999 Dec;4(4):272-80. doi: 10.1046/j.1523-5378.1999.99311.x. Helicobacter. 1999. PMID: 10597398

3

A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States.

Rupnow MF, Shachter RD, Owens DK, Parsonnet J. Rupnow MF, et al. Emerg Infect Dis. 2000 May-Jun;6(3):228-37. doi: 10.3201/eid0603.000302. Emerg Infect Dis. 2000. PMID: 10827112 Free PMC article.

4

Quantifying the population impact of a prophylactic Helicobacter pylori vaccine.

Rupnow MF, Shachter RD, Owens DK, Parsonnet J. Rupnow MF, et al. Vaccine. 2001 Dec 12;20(5-6):879-85. doi: 10.1016/s0264-410x(01)00401-7. Vaccine. 2001. PMID: 11738753

5

Cost effectiveness of topiramate in the prevention of migraines in the United States: an update.

Brown JS, Rupnow MF, Neumann P, Friedman M, Menzin J. Brown JS, et al. Among authors: rupnow mf. Manag Care Interface. 2006 Dec;19(12):31-8. Manag Care Interface. 2006. PMID: 17274479

6

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. Edwards NC, et al. Among authors: rupnow mf. Pharmacoeconomics. 2005;23(3):299-314. doi: 10.2165/00019053-200523030-00009. Pharmacoeconomics. 2005. PMID: 15836010

7

Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.

Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Boccuzzi SJ. Silberstein SD, et al. Among authors: rupnow mf. Headache. 2007 Apr;47(4):500-10. doi: 10.1111/j.1526-4610.2007.00754.x. Headache. 2007. PMID: 17445099

8

The risks and costs of multiple-generic substitution of topiramate.

Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J. Duh MS, et al. Among authors: rupnow mf. Neurology. 2009 Jun 16;72(24):2122-9. doi: 10.1212/WNL.0b013e3181aa5300. Neurology. 2009. PMID: 19528520

9

Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.

Edell WS, Rupnow MF. Edell WS, et al. Among authors: rupnow mf. Manag Care Interface. 2003 May;16(5):64-7. Manag Care Interface. 2003. PMID: 12789866

10

Evaluation of resource utilization and cost burden before and after an employer-based migraine education program.

Page MJ, Paramore LC, Doshi D, Rupnow MF. Page MJ, et al. Among authors: rupnow mf. J Occup Environ Med. 2009 Feb;51(2):213-20. doi: 10.1097/JOM.0b013e318192bcd1. J Occup Environ Med. 2009. PMID: 19209043

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page